...
首页> 外文期刊>Diabetes, obesity & metabolism >One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
【24h】

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

机译:地格列克胰岛素和利拉鲁肽固定组合对2型糖尿病患者的一年疗效和安全性:将26周延长至26周主要试验的结果

获取原文
获取原文并翻译 | 示例

摘要

Aims: To confirm, in a 26-week extension study, the sustained efficacy and safety of a fixed combination of insulin degludec and liraglutide (IDegLira) compared with either insulin degludec or liraglutide alone, in patients with type 2 diabetes.
机译:目的:在一项为期26周的扩展研究中,证实2型糖尿病患者中,胰岛素德格列酯和利拉鲁肽固定组合(IDegLira)与单独使用胰岛素德格列酯或利拉鲁肽相比具有持续的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号